DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Clinical trials for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets immune system to fight tough cancers
Disease control Recruiting nowThis is a first-in-human study testing a new oral drug called NX-1607 in adults with advanced cancers that have stopped responding to standard treatments. The main goal is to find a safe dose and see how well the body handles the drug, both alone and combined with a common chemot…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Apr 01, 2026 19:56 UTC
-
Last-Hope drug offered to patients with aggressive lymphoma
Disease control AVAILABLEThis program provides access to an experimental drug called odronextamab for people with advanced B-cell lymphomas that have come back or stopped responding to standard treatments. It is for patients who have run out of approved treatment options. The goal is to control the cance…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for older lymphoma patients: gentler treatment strategy under study
Disease control Recruiting nowThis study is testing whether adding newer drugs (glofitamab, polatuzumab, and obinutuzumab) to standard lymphoma treatment works better for older adults with aggressive B-cell lymphoma. Researchers want to see if this combination can effectively control the cancer while causing …
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:40 UTC
-
Last-Chance CAR-T offered when standard treatment Can't be made
Disease control AVAILABLEThis program provides access to a CAR-T cell therapy called tisagenlecleucel (Kymriah) for patients with acute lymphoblastic leukemia or diffuse large B-cell lymphoma when their personalized treatment product doesn't meet the usual manufacturing standards for commercial release. …
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope to keep aggressive cancer at bay after initial treatment
Disease control Recruiting nowThis study is testing whether a drug called chidamide can help prevent a type of aggressive blood cancer (DLBCL) from coming back in patients who also have hepatitis B. It is for people whose cancer initially responded well to standard chemotherapy. The goal is to see if taking c…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE3 • Sponsor: Ou Bai, MD/PHD • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
New Two-Pronged cancer therapy aims to outsmart relapsed lymphoma
Disease control Recruiting nowThis study is testing a new, experimental CAR T-cell therapy called ronde-cel against currently approved CAR T-cell therapies for patients with aggressive large B-cell lymphoma that has returned or not responded to initial chemotherapy. The new therapy is designed to target two m…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE3 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Blood test guides extra treatment to fight lymphoma in seniors
Disease control Recruiting nowThis study is testing a personalized approach to improve outcomes for older adults with a type of blood cancer called DLBCL. After initial chemotherapy, a blood test checks for tiny traces of leftover cancer. If found, patients receive an additional targeted antibody drug called …
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Danielle Wallace • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New drug trial offers hope for patients with Tough-to-Treat lymphoma
Disease control Recruiting nowThis study is testing whether an experimental drug called Rocbrutinib works better than standard therapy for adults with a specific type of aggressive lymphoma that has returned or not responded to at least two prior treatments. About 150 participants will be randomly assigned to…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New drug trial offers hope for Tough-to-Treat blood cancers
Disease control Recruiting nowThis is a first-in-human study testing a new oral drug called NX-5948 in adults with advanced B-cell blood cancers that have returned or stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. The study will enroll …
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for elderly lymphoma patients: experimental combo targets Tough-to-Treat cancer
Disease control Recruiting nowThis study is testing a new three-drug combination (Chidamide, Rituximab, and Polatuzumab Vedotin) for elderly patients with a specific, aggressive type of lymphoma who have not yet received treatment. The main goal is to see how well this regimen works to eliminate the cancer an…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
Last-Hope cancer drug offered outside clinical trials
Disease control AVAILABLEThis program provides the investigational drug selinexor to patients with certain cancers who have run out of standard treatment options and don't qualify for ongoing clinical trials. It allows doctors to request the drug for eligible patients before it receives full regulatory a…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New CAR-T therapy trial offers hope for patients with aggressive lymphoma
Disease control Recruiting nowThis study is testing a new CAR-T cell therapy called TC011 for adults with aggressive B-cell lymphoma that has come back or hasn't responded to at least two prior treatments. The main goals are to find a safe dose and see if the therapy can shrink or eliminate tumors. It is for …
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE1, PHASE2 • Sponsor: TICAROS Co., Ltd. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Engineered immune cells target aggressive brain cancer in new trial
Disease control Recruiting nowThis study is testing a new type of personalized cell therapy for adults with a hard-to-treat lymphoma that affects the brain and spinal cord. Doctors will collect a patient's own immune cells, modify them in a lab to better target the cancer, and then infuse them back into the p…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Hyungwoo Cho • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Tracking 'Living Drug' cells to improve cancer treatment
Disease control Recruiting nowThis study aims to better understand how CAR-T cell therapy works in patients with specific blood cancers (lymphoma and leukemia) in real-world settings. Researchers will closely monitor how long the modified immune cells last in the body and how well they fight the cancer. They …
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New hope for Tough-to-Treat lymphoma: adding a Brain-Penetrating drug to standard therapy
Disease control Recruiting nowThis study is testing whether adding a drug called zanubrutinib to standard chemotherapy can better control a fast-growing type of blood cancer called diffuse large B-cell lymphoma (DLBCL) in patients with high-risk features. It will enroll 50 newly diagnosed patients whose cance…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Mar 03, 2026 14:06 UTC
-
Herbal hope for cancer fatigue? trial tests capsule for Post-Chemo recovery
Symptom relief Recruiting nowThis study is testing whether a traditional Chinese medicine capsule called Xinlikang can help reduce severe fatigue and improve immune system function in people with diffuse large B-cell lymphoma who have finished their main chemotherapy. Researchers will compare the capsule to …
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2, PHASE3 • Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated Mar 30, 2026 14:29 UTC
-
Can a 6-Month health plan boost life after lymphoma?
Symptom relief Recruiting nowThis study is testing whether a 6-month personalized health plan can improve the quality of life for people who survived lymphoma. The plan includes nutrition advice, physical activity guidance, and follow-up care. Researchers will compare the results of participants who follow t…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: NA • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Symptom relief
Last updated Mar 02, 2026 15:25 UTC
-
Massive 3,000-Patient study maps Real-World blood cancer care
Knowledge-focused Recruiting nowThis study is creating a national registry to track how nearly 3,000 adults in Germany with various blood cancers are treated in real-world clinics. It aims to understand common treatment patterns, patient quality of life, and survival outcomes over time. The goal is to identify …
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:39 UTC